#147 I wonder: p-value

BrainWaves: A Neurology Podcast

• Episode: #147 I wonder: p-value
• Website: BrainWaves: A Neurology Podcast
• Feed URL: http://feeds.soundcloud.com/users/soundcloud:users:214831941/sounds.rss
• Duration: 00:27:06
• Published: 2019-09-05 11:00

One study shows that 30 minutes of exercise 5 times a week can reduce your risk of squamous cell carcinoma of the skin, p=0.001. (Let's pretend this is true). What does this mean?

Well, let's start by asking the question, how IMPORTANT is it that you reduce your risk of SCC of the skin, and how MUCH does exercise reduce that risk? If the effect of exercise is associated with a relative risk reduction of 1% in your lifetime risk of SCC, is that enough to get you to spend 1 week of your life each year on a treadmill?

In this week's "I wonder" series, Dr. Ali Hamedani joins Jim Siegler to discuss the difference between statistical significance and clinical importance, how to interpret p-values, and exactly what kinds of conclusions you should draw from clinical studies.

Produced by James E. Siegler and Ali Hamedani. Music courtesy of Jahzzar, Kevin McLeod, Sergey Cheremisinov, and the trio Grossman, Ewell and Grainger. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast.

REFERENCES

1. Gardner MJ and Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed). 1986;292:746-50.
2. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Annals of internal medicine. 1999;130:995-1004.
3. Bartolucci AA, Tendera M and Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. The American journal of cardiology. 2011;107:1796-801.
4. Pocock SJ and Stone GW. The Primary Outcome Fails - What Next? The New England journal of medicine. 2016;375:861-70.
5. Howard JF, Jr., Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R and Group RS. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. The Lancet Neurology. 2017;16:976-986.
6. Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF, Jr. and Regain Study G. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60:14-24.
7. National Institute of Neurological D and Stroke rt PASSG. Tissue plasminogen activator for acute ischemic stroke. The New England journal of medicine. 1995;333:1581-7.
8. Fritz CO, Morris PE and Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen. 2012;141:2-18.